NCT03149900View on ClinicalTrials.gov

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

July 25, 2019

Study Completion Date

July 25, 2019

Conditions
Psoriasis Vulgaris
Interventions
DRUG

Secukinumab

See Arm Description

Trial Locations (1)

23538

University Clinic Schleswig-Holstein, Lübeck

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Diamant Thaci

OTHER